SOM intends to advance the drug into a phase 2b trial later this year, and reckons it has key advantages over Lundbeck's Xenazine (tetrabenazine), a well-established VMAT2 inhibitor used to treat ...

If it does, the condition may be treated with Xenazine (tetrabenazine), a drug often used to treat movement disorders such as Huntington’s disease. In most cases, however, treatment is not necessary ...

Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics ...